IP Waiver for COVID-19 Vaccines: What the United States’ Support Means in Practice (JSON)

lexblog.com/lib/2MD8T8F7view recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "IP Waiver for COVID-19 Vaccines: What the United States’ Support Means in Practice",
    "url": "https://www.lexblog.com/2021/06/22/ip-waiver-for-covid-19-vaccines-what-the-united-states-support-means-in-practice/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-2MD8T8F7",
        "url": "https://www.lexblog.com/lib/2MD8T8F7/"
    },
    "datePublished": "2021-06-22T11:36:05-04:00",
    "dateModified": "2025-03-19T15:02:50-04:00",
    "author": {
        "@type": "Person",
        "name": "David W. Heck, Baldassare Vinti"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Proskauer Rose LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "The Patent Playbook",
    "about": "Health Care and Life Sciences",
    "sourceUrl": "https://lifesciences.proskauerroseblogs.com/?p=2083",
    "sourceStability": "may-move"
}